The Application Effect of Improved Electroconvulsive Therapy Combined with High-frequency rTMS in Patients with Schizophrenia and its Impact on Cognitive Function
DU Tiantian, LIANG Xuejun, SHI Zhenjuan, et al
No.988th Hospital of the Joint Logistic Support Force of the People's Liberation Army, Jiaozuo Henan 454000
Abstract 【Objective】To explore the application effect of modified electroconvulsive therapy (MECT) combined with high-frequency repetitive transcranial magnetic stimulation (rTMS) in patients with schizophrenia (SCH) and its impact on cognitive function. 【Methods】A total of 88 patients with schizophrenia admitted to our hospital from January 2021 to June 2023 were selected and randomly divided into an observation group and a control group using a random number table method, with 44 cases in each group. Both groups were given conventional drugs, the control group was given MECT +high-frequency rTMS non irritating treatment, and the observation group was given MECT+ high-frequency rTMS treatment. We compared the efficacy, Montreal Cognitive Assessment Scale (MoCA), Positive and Negative Symptom Scale (PANSS), serum neurotransmitters [Y-aminobutyric acid (GABA), dopamine (DA), norepinephrine (NE), 5-hydroxytryptamine (5-HT)], GQOLI-74 scores, and incidence of adverse reactions between two groups. 【Results】The clinical effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P<0.05). After treatment, the positive symptom score, negative symptom score, general psychopathological symptom score, and total score of the two groups decreased compared to before treatment. The observation group was lower than the control group, and the difference was statistically significant (P<0.05). After treatment, the GQOLI-74 and MoCA scores of both groups were higher than before treatment, and the observation group was higher than the control group, with a statistically significant difference (P<0.05). After treatment, the serum levels of NE, GABA, 5-HT, and DA in both groups were higher than before treatment, and the observation group was higher than the control group, with statistical significance (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups of patients (P>0.05). 【Conclusion】High frequency rTMS has a significant therapeutic effect on schizophrenia, regulating neurotransmitter expression, improving cognitive function, alleviating psychiatric symptoms, and improving quality of life.
[1] MASROOR A,KHOROCHKOV A,PRIETO J, et al. Unraveling the association between schizophrenia and substance use disorder-Predictors,mechanisms and treatment modifications: a systematic review[J].Cureus,2021,13(7):16722. [2] 康敏敏,李婷,黄正元,等.精神分裂症认知障碍与星形胶质细胞关系的研究进展[J].中国现代医学杂志,2020,30(6):52-56. [3] 刘新生,王仁广,陈红军,等.依托咪酯联合丙泊酚诱导全麻在精神分裂症患者MECT治疗中的应用及安全性分析[J].国际精神病学杂志,2020,47(1):104-106. [4] 蒲丽,刘可智.高频重复经颅磁刺激治疗以阴性症状为主的精神分裂症患者疗效及其持续时间观察[J].现代中西医结合杂志,2020,29(12):1280-1283. [5] 中华医学会精神科分会.中国精神障碍分类与诊断标准(CGMD-3)[M].3版.济南:山东科学技术出版社,2001:40-43. [6] 王欣,张应全,陈军升,等.阴性和阳性症状精神分裂症患者内隐记忆特点及相关因素[J].中华行为医学与脑科学杂志,2021,30(3):232-237. [7] VITA A,BARLATI S,CERASO A, et al. Effectiveness,core elements,and moderators of response of cognitive remediation for schizophrenia: a systematic review and meta-analysis of randomized clinical trials[J].JAMA Psychiatry,2021,78(8):848-858. [8] 李群,黄呈隆,蒙淑琼,等.无抽搐性电休克联合抗精神药物对复发精神分裂症急性期患者的临床疗效[J].中南医学科学杂志,2021,49(4):477-480. [9] 丁梅,施于超,曹雍华,等.阿立哌唑联合MECT对精神分裂症患者甲状腺功能及血清神经营养因子水平的影响[J].临床和实验医学杂志,2021,20(24):2655-2659. [10] 赵艳丽,黄文倩,石晶,等.重复经颅磁刺激对精神分裂症患者前脉冲抑制功能的影响[J].神经疾病与精神卫生,2020,20(4):235-240. [11] 王林平,肖岩,杨富增,等.精神分裂症患者高频重复经颅磁刺激治疗后复发的影响因素分析[J].中国医师杂志,2022,24(3):439-442. [12] 陈天意,刘登堂,介勇,等.重复经颅磁刺激应用于精神分裂症的阴性症状[J].国际精神病学杂志,2020,47(2):233-235. [13] 范桂红,何俊,庞高峰,等.无抽搐电休克疗法对精神分裂症患者的治疗效果和脑内及不同脑区神经递质水平的影响研究[J].中国全科医学,2022,25(3):325-330. [14] 方芳,方海红,宋明芬,等.细胞色素P450酶1A2、2D6与多巴胺D2受体基因多态性对奥氮平治疗精神分裂症PANSS减分率的影响[J].中国现代应用药学,2020,37(13):1621-1624.
[1]
. [J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(5): 768-770.
2024, Vol. 41 
